Mouth bacteria may predict colon cancer drug resistance
NCT ID NCT07619859
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examines if the amount of a bacteria called Fusobacterium nucleatum in colon cancer tumors is linked to how well patients respond to targeted therapies like cetuximab or panitumumab. Researchers will analyze stored tumor samples from 500 patients with metastatic colorectal cancer. The goal is to understand why some patients do not benefit from these drugs, which could lead to better treatment choices in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients with metastatic colorectal cancer will benefit from anti-EGFR therapies, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It looks at past data, so it can show links but not prove cause and effect. Results may not change practice immediately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barretos Cancer Hospital
Barretos, São Paulo, 14784-400, Brazil